Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:fibroblast growth factor receptor antagonist
go back to main search page
Accession:CHEBI:63457 term browser browse the term
Definition:An antagonist at the fibroblast growth factor receptor.
Synonyms:related_synonym: FGFR inhibitor;   FGFR inhibitors;   fibroblast growth factor receptor antagonists;   fibroblast growth factor receptor inhibitor;   fibroblast growth factor receptor inhibitors


show annotations for term's descendants           Sort by:
AZD4547 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation ISO AZD4547 results in decreased phosphorylation of AKT1 protein CTD PMID:26853465 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Akt1s1 AKT1 substrate 1 decreases phosphorylation ISO AZD4547 results in decreased phosphorylation of AKT1S1 protein CTD PMID:26853465 NCBI chr 1:95,333,186...95,339,678
Ensembl chr 1:95,332,898...95,339,677 		JBrowse link
G Frs2 fibroblast growth factor receptor substrate 2 increases phosphorylation ISO AZD4547 results in increased phosphorylation of FRS2 protein CTD PMID:26853465 NCBI chr 7:52,711,255...52,792,738
Ensembl chr 7:52,711,257...52,792,743 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta affects expression
multiple interactions		 ISO AZD4547 affects the expression of MAP1LC3B protein modified form
bafilomycin A1 affects the reaction [AZD4547 affects the expression of MAP1LC3B protein modified form]		 CTD PMID:26853465 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation ISO AZD4547 results in decreased phosphorylation of RPS6 protein CTD PMID:26853465 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 decreases expression ISO AZD4547 results in decreased expression of SREBF1 protein CTD PMID:26853465 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
lenvatinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atp5f1a ATP synthase F1 subunit alpha affects expression EXP lenvatinib affects the expression of ATP5F1A protein CTD PMID:34019861 NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794 		JBrowse link
G Cat catalase decreases expression EXP lenvatinib results in decreased expression of CAT mRNA CTD PMID:34019861 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A affects expression EXP lenvatinib affects the expression of CDKN1A protein CTD PMID:34019861 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A decreases expression EXP lenvatinib results in decreased expression of CPT1A mRNA CTD PMID:35788046 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055 		JBrowse link
G Cpt1b carnitine palmitoyltransferase 1B decreases expression EXP
ISO		 lenvatinib results in decreased expression of CPT1B mRNA; lenvatinib results in decreased expression of CPT1B protein CTD PMID:35788046 NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404 		JBrowse link
G Cpt2 carnitine palmitoyltransferase 2 decreases expression EXP
ISO		 lenvatinib results in decreased expression of CPT2 mRNA; lenvatinib results in decreased expression of CPT2 protein CTD PMID:35788046 NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095 		JBrowse link
G Dnm1l dynamin 1-like increases expression EXP lenvatinib results in increased expression of DNM1L mRNA CTD PMID:34019861 NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482 		JBrowse link
G Fis1 fission, mitochondrial 1 increases expression EXP lenvatinib results in increased expression of FIS1 mRNA CTD PMID:34019861 NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377 		JBrowse link
G Lonp1 lon peptidase 1, mitochondrial decreases expression EXP lenvatinib results in decreased expression of LONP1 protein CTD PMID:34019861 NCBI chr 9:1,447,444...1,459,771
Ensembl chr 9:1,447,447...1,459,771 		JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 increases expression EXP lenvatinib results in increased expression of MAP3K5 mRNA CTD PMID:34019861 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases expression EXP lenvatinib results in increased expression of MAPK8 mRNA CTD PMID:34019861 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mfn1 mitofusin 1 affects expression EXP lenvatinib affects the expression of MFN1 mRNA CTD PMID:34019861 NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640 		JBrowse link
G Mfn2 mitofusin 2 affects expression EXP lenvatinib affects the expression of MFN2 mRNA CTD PMID:34019861 NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342 		JBrowse link
G Mt-co1 mitochondrially encoded cytochrome c oxidase I affects expression
decreases expression		 EXP lenvatinib affects the expression of COX1 protein
lenvatinib results in decreased expression of COX1 protein		 CTD PMID:34019861 PMID:35788046 NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867 		JBrowse link
G Ndufb8 NADH:ubiquinone oxidoreductase subunit B8 affects expression EXP lenvatinib affects the expression of NDUFB8 protein CTD PMID:34019861 NCBI chr 1:243,408,656...243,413,715
Ensembl chr 1:243,408,619...243,413,817 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 decreases expression EXP lenvatinib results in decreased expression of NFE2L2 mRNA CTD PMID:34019861 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nrf1 nuclear respiratory factor 1 affects expression EXP lenvatinib affects the expression of NRF1 mRNA CTD PMID:34019861 NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328 		JBrowse link
G Opa1 OPA1, mitochondrial dynamin like GTPase increases expression EXP lenvatinib results in increased expression of OPA1 mRNA CTD PMID:34019861 NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109 		JBrowse link
G Sdhb succinate dehydrogenase complex iron sulfur subunit B decreases expression EXP lenvatinib results in decreased expression of SDHB protein CTD PMID:34019861 PMID:35788046 NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293 		JBrowse link
G Slc22a5 solute carrier family 22 member 5 decreases expression ISO
EXP		 lenvatinib results in decreased expression of SLC22A5 protein
lenvatinib results in decreased expression of SLC22A5 mRNA; lenvatinib results in decreased expression of SLC22A5 protein		 CTD PMID:35788046 NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309 		JBrowse link
G Slc25a20 solute carrier family 25 member 20 decreases expression ISO
EXP		 lenvatinib results in decreased expression of SLC25A20 protein
lenvatinib results in decreased expression of SLC25A20 mRNA; lenvatinib results in decreased expression of SLC25A20 protein		 CTD PMID:35788046 NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512 		JBrowse link
G Sod2 superoxide dismutase 2 increases expression EXP lenvatinib results in increased expression of SOD2 mRNA CTD PMID:34019861 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Ucp2 uncoupling protein 2 decreases expression EXP lenvatinib results in decreased expression of UCP2 mRNA; lenvatinib results in decreased expression of UCP2 protein CTD PMID:34019861 NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611 		JBrowse link
G Uqcrc2 ubiquinol cytochrome c reductase core protein 2 affects expression
decreases expression		 EXP lenvatinib affects the expression of UQCRC2 protein
lenvatinib results in decreased expression of UQCRC2 protein		 CTD PMID:34019861 PMID:35788046 NCBI chr 1:175,167,933...175,198,499
Ensembl chr 1:175,167,894...175,199,453 		JBrowse link
nintedanib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Tuba1a tubulin, alpha 1A decreases expression ISO nintedanib results in decreased expression of TUBA1A mRNA CTD PMID:27015953 NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186 		JBrowse link
PD173074 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of BIRC5 protein CTD PMID:27794399 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [PKI 166 co-treated with PD 173074] results in decreased expression of CCND1 protein CTD PMID:15377668 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Fgf1 fibroblast growth factor 1 multiple interactions ISO PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein] CTD PMID:15709206 NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357 		JBrowse link
G Fgfr1 Fibroblast growth factor receptor 1 decreases activity
decreases expression
multiple interactions		 ISO PD 173074 results in decreased activity of FGFR1 protein
PD 173074 results in decreased expression of FGFR1 protein
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; Arsenic Trioxide promotes the reaction [PD 173074 results in decreased expression of FGFR1 protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of FGFR1 protein]		 CTD PMID:22683780 PMID:27794399 NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350 		JBrowse link
G Fgfr3 fibroblast growth factor receptor 3 decreases activity ISO PD 173074 results in decreased activity of FGFR3 protein CTD PMID:15029211 NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341 		JBrowse link
G Fgfr4 fibroblast growth factor receptor 4 multiple interactions
decreases activity		 ISO PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein]
PD 173074 results in decreased activity of FGFR4 protein		 CTD PMID:15377668 PMID:15709206 NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242 		JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation
decreases expression
multiple interactions		 ISO PD 173074 results in decreased phosphorylation of MAPK1 protein
PD 173074 results in decreased expression of MAPK1 protein
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]		 CTD PMID:15029211 PMID:25953896 PMID:27794399 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation
decreases expression
multiple interactions		 ISO PD 173074 results in decreased phosphorylation of MAPK3 protein
PD 173074 results in decreased expression of MAPK3 protein
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein]		 CTD PMID:15029211 PMID:25953896 PMID:27794399 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [arsenic trioxide co-treated with PD 173074] results in increased expression of PARP1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in increased expression of PARP1 protein modified form; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in increased expression of PARP1 protein modified form CTD PMID:27794399 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Phlpp1 PH domain and leucine rich repeat protein phosphatase 1 multiple interactions ISO PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]; PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein] CTD PMID:25953896 NCBI chr13:22,308,532...22,530,978
Ensembl chr13:22,308,548...22,530,977 		JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase decreases expression
multiple interactions		 ISO PD 173074 results in decreased expression of RAF1 protein; PD 173074 results in decreased expression of RAF1 protein modified form
[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein; [arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein modified form; arsenic trioxide promotes the reaction [PD 173074 results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein]		 CTD PMID:27794399 NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions ISO [PKI 166 co-treated with PD 173074] results in decreased activity of RPS6KB1 protein CTD PMID:15377668 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908 		JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions
decreases expression		 ISO [Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein; [Arsenic Trioxide results in increased susceptibility to PD 173074] which results in decreased expression of SRC protein; [PD 173074 results in increased susceptibility to Arsenic Trioxide] which results in decreased expression of SRC protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein modified form]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein]
PD 173074 results in decreased expression of SRC protein; PD 173074 results in decreased expression of SRC protein modified form		 CTD PMID:27794399 NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476 		JBrowse link
G Tbx3 T-box transcription factor 3 multiple interactions ISO PD 173074 inhibits the reaction [afimoxifene results in increased expression of TBX3 protein]; PD 173074 inhibits the reaction [Estrogens results in increased expression of TBX3 protein] CTD PMID:21098263 NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA]]; PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA] CTD PMID:26800359 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19841
    role 19817
      biological role 19815
        pharmacological role 19058
          antagonist 17239
            fibroblast growth factor receptor antagonist 48
              2-amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoic acid 0
              AZD4547 6
              BGJ-398 0
              E-3810 0
              E-3810 free base 0
              PD173074 17
              SU5402 0
              brivanib + 0
              brivanib alaninate 0
              lenvatinib 24
              lenvatinib mesylate 0
              nintedanib 1
              nintedanib esylate 0
              sodium 2-amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoate 0
paths to the root